Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | PLA2G4B | P0C869 | 6/20 | 0.50 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.48 |
| ▸ | RARB | P10826 | 3/20 | 0.48 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.46 |
| ▸ | THRA | P10827 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7213167 | 1.00 | TP53 (0.51) | TP53TSHRGAARAB9ANPC1 | |
| SCHEMBL6444893 | 0.75 | POLB (0.47) | TSHRGAARAB9ANPC1LMNA | |
| SCHEMBL11126885 | 0.74 | TP53 (0.69) | TP53TSHRRAB9ANPC1LMNA | |
| SCHEMBL5219438 | 0.74 | TP53 (0.69) | TP53TSHRRAB9ANPC1LMNA | |
| SCHEMBL5219396 | 0.74 | TP53 (0.69) | TP53TSHRRAB9ANPC1LMNA | |
| SCHEMBL14672532 | 0.74 | TP53 (0.69) | TP53TSHRRAB9ANPC1LMNA | |
| SCHEMBL5215917 | 0.74 | TP53 (0.69) | TP53TSHRRAB9ANPC1LMNA | |
| SCHEMBL5215164 | 0.74 | TP53 (0.69) | TP53TSHRRAB9ANPC1LMNA | |
| SCHEMBL9636880 | 0.74 | TP53 (0.69) | TP53TSHRRAB9ANPC1LMNA | |
| SCHEMBL7213360 | 0.74 | TP53 (0.59) | TP53TSHRGAARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624309-B1 | Administering 4-heterocyclicbenzamide derivative | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-20020137968-A1 | Benzoic acid derivatives and related compounds as antiarrhythmic agents | LLOYD JOHN (US) | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137968-A1 | Benzoic acid derivatives and related compounds as antiarrhythmic agents | SCN1A, SCN1B, NR0B1 | TP53 4875/4885TSHR 2565/4885GAA 3492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.